Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20

Journal of Clinical Oncology

Volumn 25, Issue 27, 2007, Pages 4278-4284

  Arnold, Andrew M ^a   Seymour, Lesley ^a   Smylie, Michael ^a   Ding, Keyue ^a   Ung, Yee ^a   Findlay, Brian ^a   Lee, Christopher W ^a   Djurfeldt, Marina ^a   Whitehead, Marlo ^a   Ellis, Peter ^a   Goss, Glenwood ^a   Chan, Adrien ^a   Meharchand, Jacinta ^a   Alam, Yasmin ^a   Gregg, Richard ^a   Butts, Charles ^a   Langmuir, Peter ^a   Shepherd, Frances ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PLACEBO; VANDETANIB; VASCULOTROPIN INHIBITOR; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 ((1 METHYLPIPERIDIN 4 YL)METHOXY)QUINAZOLIN 4 AMINE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BRAZIL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEMOPTYSIS; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT OUTCOME; AGED; LUNG TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; QUALITY OF LIFE; SMALL CELL CARCINOMA;

ADULT; AGED; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PIPERIDINES; PLACEBOS; QUALITY OF LIFE; QUINAZOLINES; TREATMENT OUTCOME;

EID: 34948844052     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.3083     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2007. CA Cancer J Clin 57:43-66, 2007
2. National Cancer Institute of Canada. Canadian Cancer Statistics, 11-15, 2000
3. Schottenfeld D: Etiology and epidemiology of lung cancer, in Pass H, Mitchell J, Johnson D, et al (eds): Lung Cancer Principles and Practice (ed 2). Philadelphia, PA, Lippincott Williams & Wilkins, 2000
4. Ettinger D, Johnson B: Update: NCCN small cell and non-small cell lung cancer Clinical Practice Guidelines. J Natl Compr Cancer Net 3:S17-S21 (2005)
5. DeVore RF, Johnson DH: Chemotherapy for small cell lung cancer, in Pass H, Mitchell J, Johnson D, et al (eds): Lung Cancer Principles and Practice (ed 2). Philadelphia, PA, Lippincott Williams & Wilkins, 2000, pp 923-939
6. Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol 24:4539-4544, 2006
7. Logroño R, Jones DV, Faruqi S, et al: Recent advances in cell biology, diagnosis, and therapy of gastrointestinal stromal tumor (GIST). Cancer Biol Ther 3:251-258, 2004
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
9. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186, 1971
10. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355:2542-2550, 2006
11. Lucchi M, Mussi A, Fontanini G, et al: Small cell lung carcinoma (SCLC): The angiogenic phenomenon. Eur J Cardiothorac Surg 21:1105-1110, 2002
12. Michael M, Babic B, Khokha R, et al: Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 17:1802-1808, 1999
13. Ruotsalainen T, Joensuu H, Mattson K, et al: High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Cancer Epidemiol Biomarkers Prev 11:1492-1495, 2002
14. Shepherd FA, Giaccone G, Seymour L, et al: Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20:4434-4439, 2002
15. Pujol JL, Breton JL, Gervais R, et al: A prospective randomized phase III, double-blind, placebo-controlled study of thalidomide in extended-disease (ED) SCLC patients after response to chemotherapy (CT): An intergroup study FNCLCC Cleo04 - IFCT 00-01. J Clin Oncol 24:378s, 2006 (suppl; abstr 7057)
16. Kovacs MJ, Reece DE, Marcellus D, et al: A phase II study of ZD6474 (Zactima), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma: NCIC CTG IND.145. Invest New Drugs 24:529-535, 2006
17. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines). J Natl Cancer Inst 92:205-216, 2000
18. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
19. Bergman B, Aaronson NK, Ahmedzai S, et al: The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30A:635-642, 1994
20. Krug LM, Crapanzano JP, Azzoli CG, et al: lmatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: A phase II clinical trial. Cancer 103:2128-2131, 2005
21. Moore AM, Einhorn LH, Estes D, et al: Gefitinib in patients with chemo-sensitive and chemorefractory relapsed small cell cancers: A Hoosier Oncology Group phase II trial. Lung Cancer 52:93-97, 2006
22. Heymach JV, Johnson BE, Prager D, et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated non-small cell lung cancer. J Clin Oncol 24:368s, 2006 (suppl; abstr 7016)
23. Mattson K, Niiranen A, Pyrhonen S, et al: Natural interferon alfa as maintenance therapy for small cell lung cancer. Eur J Cancer 28A:1387-1391, 1992
24. Lebeau B, Salmoniere PDL, Ozenne G, et al: Alpha Interferon as maintenance therapy for small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 18:475a, 1999 (abstr 1832)
25. Kelly K, Crowley JJ, Bunn PA, et al: Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: A Southwest Oncology Group study. J Clin Oncol 13:2924-2930, 1995
26. Jett JR, Maksymiuk AW, Su JQ, et al: Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol 12:2321-2326, 1994